Biosimilar switching — “To set a form upon desired change” | Nature Reviews Rheumatology
Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial - Goll - 2019 - Journal of Internal Medicine - Wiley Online Library